(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 10. (A) BDM does not decrease actin polymer levels. Actin polymer status was measured using FACS analysis of rhodamine-phalloidin binding in myoblasts treated with vehicle, latB (0.5 µM) or BDM (15 mM). (Expressed as a percentage of vehicle control, mean ± s.e.m.; n=2). (B) MyoD expression responds differentially to actin depolymerizing drugs. Myoblasts were treated with vehicle (a,b), 15 mM BDM (c,d), 0.5 µM latB (e,f) or 0.5 µM cytoD (g,h) for 18 hours before staining for MyoD. Numbers represent the percentage of MyoD-positive cells. Scale bar: 10 µm.